Chesnara PLC (LSE:CSN) saw operating capital generation jump 79% to £96 million in the first half. CEO Steve Murray also highlighted the group's 185% solvency coverage ratio and an active acquisition pipeline.

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has raised £1.3 million to push forward its CNS drug pipeline. That includes trials for alcohol use disorder and addiction treatments.

hVIVO PLC (AIM:HVO) has bought CRS Berlin to expand into dermatology and women's health trials. The CEO says it opens up new markets and cross-selling opportunities in Germany.

Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S) has completed drone battery testing with QinetiQ on its sulfur cathode material. Cells showed barely any degradation even after 50 aggressive test cycles.

Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) is expecting a strong flow of assay results over the coming weeks at Mushima North. Those results should feed into a maiden resource estimate by year-end.

Iofina PLC (AIM:IOF, OTC:IOFNF) is ramping up iodine production at its IO#11 plant with a new brine source. Its next plant, IO#12, should be online before the end of the quarter.

Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.